Jazz Pharmaceuticals to Acquire Actio Biosciences for $820 Million

Jazz Pharmaceuticals has agreed to acquire privately held Actio Biosciences in a deal worth up to $1.32 billion, adding an experimental precision medicine for a rare form of epilepsy to its growing neurology portfolio.

Under the definitive agreement, Jazz will pay $820 million upfront to acquire Actio, with an additional $500 million available in contingent payments tied to future development and other milestones.

The centerpiece of the acquisition is ABS-1230, an experimental small-molecule drug designed to selectively inhibit the KCNT1 ion channel. Actio describes the therapy as a first-in-class precision treatment for KCNT1-positive epilepsy, a rare genetic disorder that causes severe developmental and epileptic encephalopathy.

KCNT1-positive epilepsy affects an estimated 2,500 people in the United States. The condition can be particularly devastating when it begins in infancy. Around 80% of patients develop the disease during their first year of life, and many children experience dozens or even hundreds of seizures each day despite treatment with available antiseizure medicines.

The disease can also severely affect development. Some children with early-onset KCNT1 epilepsy never reach basic milestones such as walking or speaking, while others may not survive into adulthood. Patients whose disease begins later in life can experience disruptive seizures during sleep, along with cognitive and psychiatric complications.

There are currently no therapies approved by the U.S. Food and Drug Administration specifically for KCNT1-positive epilepsy, giving ABS-1230 a potential opportunity to address a significant unmet medical need.

The drug has already produced early clinical data showing meaningful reductions in seizures among children with KCNT1 epilepsy. Actio is now testing ABS-1230 in the Phase 1b/2a KYRON study, which is intended to support a potential regulatory filing in the United States.

ABS-1230 has received several FDA designations intended to support development for rare diseases. These include Fast Track, Rare Pediatric Disease and Orphan Drug designations. The program has also been accepted into the FDA’s Rare Disease Evidence Principles, or RDEP, program, which is designed to support more efficient development of treatments for ultra-rare diseases.

For Jazz, the acquisition expands its existing position in epilepsy and adds another potential therapy to a portfolio that includes Epidiolex. The company said ABS-1230 could also have applications beyond KCNT1-positive epilepsy, with opportunities to investigate the drug in other genetically defined epilepsy disorders.

Renee Gala, president and CEO of Jazz Pharmaceuticals, said the acquisition strengthens the company’s focus on rare and severe epilepsies. She pointed to the early clinical results for ABS-1230 as encouraging and said Jazz plans to work with patients, families and regulators as development progresses.

Actio CEO David Goldstein said the company selected Jazz because of its development capabilities and commercial reach, which could help move ABS-1230 toward patients more quickly.

The transaction reflects growing interest among pharmaceutical companies in genetically targeted treatments for rare neurological diseases. Rather than treating seizures broadly, precision therapies such as ABS-1230 are designed to address specific biological drivers of disease.

If the ongoing clinical development is successful, ABS-1230 could potentially become the first approved treatment specifically targeting KCNT1-positive epilepsy in the U.S. The acquisition also gives Jazz an opportunity to expand its rare epilepsy business into additional genetically defined patient populations.